News >

Larotrectinib Elicits Clinically Meaningful PFS Improvement Through GMI in TRK Fusion+ Cancers

Wayne Kuznar
Published: Friday, Oct 04, 2019

Antoine Italiano, MD, professor of medical oncology, Institut Bergonie, Bordeaux, France

Antoine Italiano, MD

Larotrectinib (Vitrakvi) demonstrated a clinically meaningful improvement in progression-free survival (PFS) compared with time to progression (TTP) on prior treatment in patients with TRK fusion–positive cancers using a measure known as the growth modulation index (GMI), according to results of an analysis presented at the 2019 ESMO Congress. 

Caveats to the data, according to the authors, are that: 1) GMI underestimates the clinical benefit in patients on treatment who have not progressed at the time of analysis, 2) patients with the poorest prognosis may have been excluded as patients had to have received at least 1 prior line of therapy for inclusion, and 3) TTP data on the most recent prior treatment were provided by physicians.
Italinao A, Nanda S, Keating K, et al. Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients. Presented at 2019 ESMO Congress; September 27-October 2, 2019; Barcelona, Spain. Abstract 485P.Nat Med. doi:10.1038/nm.4118.

 
<<< View more from the 2019 ESMO Congress
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x